Fabry Disease Market Research Reports & Industry Analysis

• Global Fabry Disease Treatment Market Growth (Status and Outlook) 2023-2029

  Feb 16, 2023  |  Published by: LP Information, Inc.  |  USD 3,660

  ... by abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system. LPI (LP Information)' newest research report, the ... Read More

• Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029

  Jan 25, 2023  |  Published by: Bizwit Research & Consulting  |  USD 4,950

  ... End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029 Global Enzyme Replacement Therapy Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth ... Read More

• Fabry Disease Market by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2023-2028

  Jan 16, 2023  |  Published by: IMARC Services Pvt. Ltd.  |  USD 2,999

  ... 1.88 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.88 Billion by 2028, exhibiting a growth rate (CAGR) of 7.26% during 2023-2028. The increasing number of patients suffering from fabry ... Read More

• Global Enzyme Replacement Therapy Market - 2022-2029

  Oct 18, 2022  |  Published by: DataM Intelligence 4Market Research LLP  |  USD 4,350

  ... of 5.1 % during the forecast period (2022-2029). Enzyme Replacement Therapy (ERT) is the treatment involved for rare diseases. According to Global genes.org, around 80.0% of rare diseases are categorized under genetic origin. There are ... Read More

• LATAM Fabry Disease Market, by Therapy Type (Enzyme Replacement Therapy (Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Pegunigalsidase Alfa (PRX-102, Phase III)) Chaperon Therapy (Migalastat (Galafold Phase III)), Substrate Reduction Therapy (Lucerastat (Phase III), Venglustat (Phase III))), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospitals Pharmacies, Online pharmacies, Retail Pharmacies), and by Country (Brazil, Argentina, Mexico, Rest of Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  Sep 26, 2022  |  Published by: Coherent Market Insights  |  USD 4,500

  ... III))), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospitals Pharmacies, Online pharmacies, Retail Pharmacies), and by Country (Brazil, Argentina, Mexico, Rest of Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - ... Read More

• Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End U

  May 11, 2022  |  Published by: Coherent Market Insights  |  USD 4,500

  ... (North America Latin America Europe Asia Pacific Middle East Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 The deficiency of enzymes that causes a specific disease condition called lysosomal storage disease includes ... Read More

• Fabry Disease - Market Insight, Epidemiology And Market Forecast - 2032

  May 01, 2022  |  Published by: DelveInsight  |  USD 7,500

  ... trends of Fabry Disease in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Fabry Disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, ... Read More

• Fabry Disease - Epidemiology Forecast - 2032

  May 01, 2022  |  Published by: DelveInsight  |  USD 3,950

  ... the United Kingdom), and Japan. Fabry Disease: Disease Understanding Fabry Disease Overview Fabry disease is an inherited lysosomal storage disease caused by a nonfunctional or only partially functional enzyme, alpha-galactosidase A (α-gal A). Decreased activity ... Read More

• Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Apr 29, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  ... provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an X-linked lysosomal disorder that results in abnormal deposits of globotriaosylceramide in blood vessel walls throughout the body. It is caused ... Read More

• Fabry Disease - Epidemiology Forecast to 2032

  Jan 01, 2022  |  Published by: DelveInsight  |  USD 3,950

  ... France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Fabry Disease Understanding The DelveInsight Fabry Disease ... Read More

< prev 1 2 next >